Drug Trial Radar · NCT03971071
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
620
Actual
Start
Oct 7, 2019
Primary completion
Dec 1, 2022
Study completion Jun 13, 2023
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jun 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication overuse headache (MOH).
Conditions
- Migraine Headache
Interventions
Erenumab 70 mgDrug
Erenumab once every 4 weeks. Subcutaneous injection.
Erenumab 140 mgDrug
Erenumab once every 4 weeks. Subcutaneous injection.
PlaceboDrug
Placebo once every 4 weeks. Subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Absence of Medication Overuse Headaches (MOH) at Month 6Time frame: Months 4, 5, and 6 (weeks 13 through 24) of the DBTP
Locations
94 sites in 12 countries. Site status is shown where the registry gives one.
Core Healthcare Group
Cerritos, California
Axiom Research
Colton, California
Clinical Research Institute
Los Angeles, California
The George Washington Medical Faculty Associates
Washington D.C., District of Columbia
University of Miami Miller School of Medicine
Miami, Florida
Floridian Clinical Research LLC
Miami Lakes, Florida
Clinical Neuroscience Solutions
Orlando, Florida
Emerald Coast Center for Neurological Disorders
Pensacola, Florida
University of South Florida
Tampa, Florida
Saint Lukes Clinic
Meridian, Idaho
Fort Wayne Neurological Center
Fort Wayne, Indiana
College Park Family Care Center
Overland Park, Kansas
Collective Medical Research
Prairie Village, Kansas
University of Kentucky
Lexington, Kentucky
DelRicht Research
New Orleans, Louisiana
Neurology Center of New England PC
Foxborough, Massachusetts
Michigan Head Pain and Neurological Institute
Ann Arbor, Michigan
Clinical Research Institute Inc
Minneapolis, Minnesota
Citizens Memorial Healthcare
Bolivar, Missouri
Mercy Research
St Louis, Missouri
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Dent Neurosciences Research Center
Amherst, New York
Onsite Clinical Solutions LLC
Charlotte, North Carolina
Clinical Trial Investigator Clinical Research Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Allegheny Health Network Cancer Institute at Mellon Pavilion
Pittsburgh, Pennsylvania
Preferred Primary Care Physicians, Inc
Pittsburgh, Pennsylvania
Nashville Neuroscience Group
Nashville, Tennessee
Texas Neurology, PA
Dallas, Texas
Wasatch Clinical Research LLC
Salt Lake City, Utah
Marshall University
Huntington, West Virginia
Aurora BayCare Medical Center
Green Bay, Wisconsin
Holdsworth House Medical Practice
Sydney, New South Wales, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Medizinische Universitaet Innsbruck
Innsbruck, Austria
Klinikum Klagenfurt am Woerthersee
Klagenfurt, Austria
Konventhospital der Barmherzigen Brueder Linz
Linz, Austria
Universitaetsklinikum Allgemeines Krankenhaus Wien
Vienna, Austria
Neurologie Brno sro
Brno, Czechia
Fakultni nemocnice u svate Anny v Brne
Brno, Czechia
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.